Dr. Priyank Bhatt
M.S., M.Ch,
Director, Department of Cardiovascular
and Thoracic Surgery, SAL Hospital, Gujarat

The study aimed to compare the impact of sacubitril/valsartan on life-threatening arrhythmias, atrial fibrillation,  echocardiography parameters, and congestion rate in heart failure with reduced ejection fraction (HFrEF) patients according to the status of diabetes mellitus. 240 patients with HFrEF from 2016 to 2020 were treated with sacubitril/valsartan and separated to concomitant diabetes mellitus or no diabetes mellitus. Over a 24-month follow-up period, significant changes were noted in both subgroups, with non-diabetes patients experiencing an increased median left ventricular ejection fraction (EF) and
decreased NT-proBNP and troponin-I levels. No significant changes were found in laboratory parameters, and the tricuspid annular plane systolic excursion was significantly increased in non-diabetes patients. The congestion rate decreased significantly in both groups, with the all-cause mortality rate being higher in patients with diabetes mellitus compared to those without diabetes. The study concluded that sacubitril/valsartan reverses cardiac remodelling in non-diabetes patients but reduces congestion rate in diabetes and non-diabetes patients.

Click Here to view the article:

John Wiley & Sons, Inc.